natgillin/translations-raw huggingface dataset:
Progressive multifocal leukoencephalopathy (PML) has been reported under fingolimod treatment since marketing authorization (see section 4.8). 
Po izdaji dovoljenja za promet z zdravilom so pri zdravljenju s fingolimodom poročali o progresivni multifokalni levkoencefalopatiji (PML) (glejte poglavje 4.8).
During routine MRI, physicians should pay attention to PML suggestive lesions. 
Zdravniki morajo biti med rednim magnetno resonančnim slikanjem pozorni na lezije, ki bi lahko bile znak PML.
Not known (frequency cannot be estimated from the available data) Risk of a rare brain infection called progressive multifocal leukoencephalopathy (PML). 
Tveganje za redko okužbo možganov, imenovano progresivna multifokalna levkoencefalopatija (PML).
Package Leaflet: 
Navodilo za uporabo:
This overview was last updated in 07-2019. 
Povzetek je bil nazadnje posodobljen 07-2019.
Symtuza received a marketing authorisation valid throughout the EU on 21 September 2017. 
Za zdravilo Symtuza je bilo 21. septembra 2017 izdano dovoljenje za promet, veljavno po vsej EU.
Other information about Symtuza 
Druge informacije o zdravilu Symtuza
Overall, 75% of patients taking Symtuza (77 patients out of 103) achieved this reduction after 24 weeks of treatment, which was similar to the 74% (37 of 50) of patients who achieved it with the comparator. 
Skupno je do takšnega zmanjšanja po 24 tednih zdravljenja prišlo pri 75 % (77 od 103) bolnikov, ki so jemali zdravilo Symtuza , kar je bilo primerljivo s 74 % (37 od 50) bolnikov, ki so to dosegli s primerjalnim zdravilom.
What measures are being taken to ensure the safe and effective use of Symtuza? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Symtuza?
Further information on Symtuza can be found on the Agency's website: ema.europa.eu/en/medicines/human/EPAR/symtuza. 
Nadaljnje informacije o zdravilu Symtuza so na voljo na spletni strani agencije: ema.europa.eu/en/medicines/human/EPAR/symtuza.
The European Medicines Agency decided that Symtuza's benefits are greater than its risks and it can be authorised for use in the EU. 
Evropska agencija za zdravila je zaključila, da so koristi zdravila Symtuza večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
HIV-1 is a virus that causes acquired immune deficiency syndrome (AIDS). 
HIV-1 je virus, ki povzroča sindrom pridobljene imunske pomanjkljivosti (aids).
It must also not be taken with certain medicines that can reduce the effectiveness of Symtuza, as well as medicines that can increase the risk of serious side effects. 
Prav tako se ne sme jemati skupaj z nekaterimi zdravili, ki lahko zmanjšajo njegovo učinkovitost, in zdravili, ki lahko povečajo tveganje za resne neželene učinke.
Why is Symtuza authorised in the EU? 
Zakaj je bilo zdravilo Symtuza odobreno v EU?
What benefits of Symtuza have been shown in studies? 
Kakšne koristi je zdravilo Symtuza izkazalo v študijah?
An overview of Symtuza and why it is authorised in the EU 
Pregled zdravila Symtuza in zakaj je odobreno v EU
As for all medicines, data on the use of Symtuza are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Symtuza stalno spremljajo.
Side effects reported with Symtuza are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Symtuza, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
Symtuza contains four active substances which work in different ways against HIV: 
Zdravilo Symtuza vsebuje štiri učinkovine, ki različno delujejo proti virusu HIV:
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Symtuza have been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Symtuza upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
Effectiveness was measured by a reduction in viral load (the amount of HIV-1 in the blood) to less than 50 copies/ml. 
Učinkovitost so merili z zmanjšanjem virusnega bremena (količine virusa HIV-1 v krvi) pod 50 kopij/ml.
What is Symtuza and what is it used for? 
Kaj je zdravilo Symtuza in za kaj se uporablja?
Because the individual active substances of Symtuza have previously been shown to be effective and are authorised for use in the treatment of HIV infection, studies were mainly carried out to show that Symtuza produced similar levels of active substances in the blood as the active substances given separately. 
Ker so za posamezne učinkovine zdravila Symtuza že predhodno dokazali, da so učinkovite in so odobrene za zdravljenje okužbe z virusom HIV, so bile študije opravljene predvsem z namenom dokazovanja, da zdravilo Symtuza ustvari enake ravni učinkovin v krvi kot ločeno dane učinkovine.
Symtuza must not be taken by patients with severely reduced liver function. 
Zdravila Symtuza ne smejo uporabljati bolniki s hudo okvaro jeter.
The most common side effects with Symtuza (which may affect more than 1 in 10 people) are diarrhoea, headache and rash. 
Najpogostejši neželeni učinki zdravila Symtuza (ki se lahko pojavijo pri več kot 1 bolniku od 10) so driska, glavobol in izpuščaj.
Symtuza is an antiviral medicine used to treat human immunodeficiency virus type 1 (HIV-1) in adults and adolescents aged from 12 years (and weighing at least 40 kg). 
Symtuza je protivirusno zdravilo, ki se uporablja za zdravljenje okužbe z virusom humane imunske pomanjkljivosti tipa 1 (HIV-1) pri odraslih in mladostnikih (starejših od 12 let in s telesno maso vsaj 40 kg).
Symtuza does not cure HIV-1 infection or AIDS, but it may hold off the damage to the immune system and the development of infections and diseases associated with AIDS. 
Zdravilo Symtuza ne ozdravi okužbe z virusom HIV-1 ali aidsa, lahko pa upočasni slabšanje imunskega sistema ter prepreči razvoj okužb in bolezni, povezanih z aidsom.
• Darunavir is a type of antiviral agent called a ‘protease inhibitor'. 
• darunavir je vrsta protivirusnega sredstva, imenovanega „zaviralec proteaze“.
For more information about using Symtuza, see the package leaflet or contact your doctor or pharmacist. 
Za več informacij glede uporabe zdravila Symtuza glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
What are the risks associated with Symtuza? 
Kakšna tveganja so povezana z zdravilom Symtuza?
It blocks protease, an enzyme of the virus that allows it to reproduce itself in the cells it has infected. 
Zavira proteazo, tj. virusni encim, ki virusu omogoča, da se razmnožuje v celicah, ki jih je okužil.
Symtuza (darunavir / cobicistat / emtricitabine / tenofovir alafenamide) 
Symtuza (darunavir/kobicistat/emtricitabin/alafenamidtenofovirat)
By blocking protease, Symtuza reduces the amount of HIV-1 in the blood and keeps it at a low level. 
Zdravilo Symtuza z zaviranjem proteaze zniža količino virusa HIV-1 v krvi in jo zadržuje na nizki ravni;
Symtuza is available as tablets, each containing 800 mg darunavir, 150 mg cobicistat, 200 mg emtricitabine and 10 mg tenofovir alafenamide. 
Zdravilo Symtuza je na voljo v obliki tablet, od katerih vsaka vsebuje 800 mg darunavirja, 150 mg kobicistata, 200 mg emtricitabina in 10 mg alafenamidtenofovirata.
Because tenofovir alafenamide is effective at a lower dose than tenofovir disoproxil, Symtuza offers the possibility of reduced side effects. 
Ker je alafenamidtenofovirat učinkovit pri manjšem odmerku kot dizoproksiltenofovirat, zdravilo Symtuza ponuja možnost zmanjšanja neželenih učinkov.
The active substances in Symtuza have already been shown to be effective when used individually, and combining them in a single tablet simplifies treatment. 
Dokazali so že, da so učinkovine v zdravilu Symtuza učinkovite, kadar se uporabljajo posamezno, če pa so združene v eni tableti, je zdravljenje enostavnejše.
In addition, one main study compared Symtuza with another antiviral medicine containing darunavir, cobicistat, emtricitabine and tenofovir disoproxil in 153 adult patients with HIV who had not been previously treated. 
Poleg tega so izvedli eno glavno študijo, v kateri so zdravilo Symtuza primerjali z drugim protivirusnim zdravilom, ki vsebuje darunavir, kobicistat, emtricitabin in dizoproksiltenofovirat, pri 153 odraslih bolnikih z okužbo z virusom HIV, ki se predhodno še niso zdravili.
For more information on the medicines that should not be taken with Symtuza, see the package leaflet. 
Za več informacij o zdravilih, ki se ne smejo jemati sočasno z zdravilom Symtuza, glejte navodilo za uporabo.
• Tenofovir alafenamide is a ‘prodrug' of tenofovir, meaning that it is converted into the active substance tenofovir in the body. 
• alafenamidtenofovirat je „predzdravilo“ tenofovirja, kar pomeni, da se v učinkovino tenofovir pretvori v telesu.
• Emtricitabine is also a reverse transcriptase inhibitor and it works in the same way as tenofovir. 
• emtricitabin je zaviralec reverzne transkriptaze in deluje enako kot tenofovir.
Symtuza can only be obtained with a prescription and treatment should be started by a doctor who is experienced in managing HIV infection. 
Predpisovanje in izdaja zdravila Symtuza je le na recept, zdravljenje pa mora uvesti zdravnik z izkušnjami z zdravljenjem okužb z virusom HIV.
• Cobicistat acts as a ‘booster' to increase the effects of darunavir, by slowing down the breakdown of darunavir and therefore prolonging its antiviral activity in the body. 
• kobicistat deluje kot „ojačevalec“ in okrepi učinke darunavirja, tako da upočasni njegovo hitrost razgradnje in s tem podaljša čas njegovega delovanja v telesu;
Symtuza was also as effective as a similar combination medicine containing tenofovir disoproxil in place of tenofovir alafenamide. 
Zdravilo Symtuza je bilo tudi tako učinkovito kot podobno kombinirano zdravilo, ki namesto alafenamidtenofovirata vsebuje dizoproksiltenofovirat.
Tenofovir is a reverse transcriptase inhibitor, which means that it blocks the activity of the enzyme, reverse transcriptase, that the virus needs to reproduce itself. 
Tenofovir je zaviralec reverzne transkriptaze, kar pomeni, da zavira delovanje reverzne transkriptaze, drugega encima, ki virusu omogoča razmnoževanje;
How is Symtuza used? 
Kako se zdravilo Symtuza uporablja?
How does Symtuza work? 
Kako zdravilo Symtuza deluje?
Symtuza contains the active substances darunavir, cobicistat, emtricitabine and tenofovir alafenamide. 
Zdravilo Symtuza vsebuje učinkovine darunavir, kobicistat, emtricitabin in alafenamidtenofovirat.
For the full list of side effects reported with Symtuza, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Symtuza, glejte navodilo za uporabo.
This overview was last updated in 08-2018. 
Povzetek je bil nazadnje posodobljen 08-2018.
However, given the extreme rarity of the condition, the safety database is small and rare events are not expected to be captured during the clinical studies. 
Vendar je glede na izjemno redkost bolezni zbirka podatkov o varnosti majhna in tako ni možno pričakovati, da bi se med kliničnimi študijami zabeležili redki neželeni učinki.
Further information on Coagadex can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Nadaljnje informacije za zdravilo Coagadex so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The European Medicines Agency decided that the benefits of Coagadex are greater than its risks and it can be authorised for use in the EU. 
Evropska agencija za zdravila je zaključila, da so koristi zdravila Coagadex večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
What measures are being taken to ensure the safe and effective use of Coagadex? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Coagadex?
Coagadex received a marketing authorisation valid throughout the EU on 16 March 2016. 
Za zdravilo Coagadex je bilo 16. marca 2016 izdano dovoljenje za promet, veljavno po vsej EU.
The main measure of effectiveness was based on the doctor's and patient's assessment of how well the treatment worked in preventing and treating bleeding episodes. 
Glavno merilo učinkovitosti je temeljilo na zdravnikovi in bolnikovi oceni, kako učinkovito je bilo zdravljenje pri preprečevanju in zdravljenju epizod krvavitev.
Coagadex has been investigated in one main study involving 16 patients with hereditary factor X deficiency aged 12 to 58 years. 
Zdravilo Coagadex je bilo raziskano v eni glavni študiji, ki je vključevala 16 bolnikov s pomanjkanjem faktorja X, starih od 12 do 58 let.
For the treatment of bleeding, 187 bleeding episodes were recorded and assessed, and treatment with Coagadex was rated as ‘excellent' or ‘good' for 98.4% of bleeding episodes. 
Pri zdravljenju krvavitev je bilo zabeleženih in ocenjenih 187 epizod krvavitev, pri čemer je bilo zdravljenje z zdravilom Coagadex ocenjeno kot „odlično“ ali „dobro“ v 98,4 % epizod krvavitev.
In a study with 9 children aged less than 12 years (4 of whom were under4 years of age), a routine preventive treatment with Coagadex over 6 months was rated as excellent in reducing or preventing bleeding episodes. 
V študiji pri devetih otrocih, mlajših od 12 let (od katerih so bili štirje mlajši od štirih let) je bilo šestmesečno rutinsko profilaktično zdravljenje z zdravilom Coagadex ocenjeno kot odlično za zmanjševanje ali preprečevanje epizod krvavitev.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Coagadex have been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Coagadex upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
The most common side effects with Coagadex (which may affect up to 1 in 10 people) are pain or redness at the injection site, fatigue (tiredness), and back pain. 
Najpogostejši neželeni učinki zdravila Coagadex (ki se lahko pojavijo pri največ 1 od 10 bolnikov) so bolečina ali pordelost na mestu injiciranja, utrujenost in bolečina v hrbtu.
As for all medicines, data on the use of Coagadex are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Coagadex stalno spremljajo.
Coagadex (human coagulation factor X) 
Coagadex (humani koagulacijski faktor X)
The Agency considered the lack of specific therapies for factor X deficiency, and concluded that Coagadex was effective at treating and preventing bleeding in patients with the condition. 
Agencija je upoštevala pomanjkanje specifičnih zdravljenj pomanjkanja faktorja X in zaključila, da je bilo zdravilo Coagadex učinkovito pri zdravljenju in preprečevanju krvavitev pri bolnikih s tem stanjem.
For more information about using Coagadex, see the package leaflet or contact your doctor or pharmacist. 
Za več informacij glede uporabe zdravila Coagadex glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
The dose and frequency of the injections depend on the severity of the patient's factor X deficiency, the extent and location of the bleeding and the patient's condition and bodyweight. 
Odmerek in pogostnost injiciranja sta odvisna od resnosti bolnikovega pomanjkanja faktorja X, obsega in mesta krvavitve ter bolnikovega stanja in telesne mase.
In these patients, blood clots do not form properly, resulting in bleeding that does not stop easily and poor wound healing. 
Pri teh bolnikih se krvni strdek ne oblikuje pravilno, zaradi česar se krvavitev ne ustavi zlahka in se rana slabo celi.
These reactions have not been reported during clinical studies with Coagadex. 
O teh reakcijah med kliničnimi študijami z zdravilom Coagadex niso poročali.
Factor X deficiency is rare and Coagadex was designated an ‘orphan medicine' (a medicine used in rare diseases) on 14 September 2007. 
Pomanjkanje faktorja X je redko, zato je bilo zdravilo Coagadex 14. septembra 2007 določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni).
Coagadex is given by injection into a vein. 
Zdravilo Coagadex se daje z injekcijo v veno.
Why is Coagadex authorised in the EU? 
Zakaj je bilo zdravilo Coagadex odobreno v EU?
An overview of Coagadex and why it is authorised in the EU 
Pregled zdravila Coagadex in zakaj je odobreno v EU
Other information about Coagadex 
Druge informacije o zdravilu Coagadex
In total, 10 bleeds were reported in the study, of which 4 were treated with Coagadex. 
Skupaj so v študiji poročali o desetih krvavitvah, od katerih so z zdravilom Coagadex zdravili štiri.
Side effects reported with Coagadex are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Coagadex, se skrbno ovrednotijo in po potrebi sprejmejo ukrepi za zaščito bolnikov.
Hypersensitivity (allergic) reactions can occur rarely in patients treated for bleeding disorders (in up to 1 patient in 1,000) and can be severe in some cases. 
Pri bolnikih, zdravljenih zaradi motenj krvavitve (pri do 1 od 1 000 bolnikov) se redko lahko pojavijo preobčutljivostne (alergijske) reakcije, ki so lahko v nekaterih primerih hude.
The side effects of Coagadex were considered manageable and of mild or moderate intensity. 
Neželeni učinki zdravila Coagadex so bili ocenjeni kot obvladljivi ter blage ali zmerne jakosti.
What benefits of Coagadex have been shown in studies? 
Kakšne koristi zdravila Coagadex so se pokazale v študijah?
Patients received Coagadex either to treat any spontaneous bleeding during the treatment period or to prevent bleeding during surgery. 
Bolniki v študiji so prejeli zdravilo Coagadex za zdravljenje kakršne koli spontane krvavitve v obdobju zdravljenja ali za preprečevanje krvavitve med kirurškim posegom.
For 3 minor surgeries during the study, Coagadex was rated as excellent in preventing bleeding episodes. 
Pri treh manjših kirurških posegih, ki so jih opravili med študijo, je bilo zdravilo Coagadex ocenjeno kot odlično za preprečevanje epizod krvavitev.
Patients may inject Coagadex themselves at home once they have been trained appropriately. 
Bolniki si lahko po primernem usposabljanju zdravilo Coagadex injicirajo sami doma.
What is Coagadex and what is it used for? 
Kaj je zdravilo Coagadex in za kaj se uporablja?
What are the risks associated with Coagadex? 
Kakšna tveganja so povezana z zdravilom Coagadex?
A single infusion of Coagadex was sufficient to control each treated bleeding event. 
Ena infuzija zdravila Coagadex je zadostovala za nadzor posamezne zdravljene krvavitve.
Patients with hereditary factor X deficiency lack factor X, a protein needed to form the blood clot that stops wounds from bleeding. 
Bolniki z dednim pomanjkanjem faktorja X nimajo dovolj faktorja X, beljakovine, ki je potrebna za nastanek krvnega strdka, ki zaustavi krvavenje iz rane.
The active substance in Coagadex is human factor X isolated from the plasma of blood donors. 
Učinkovina zdravila Coagadex je humani faktor X, pridobljen iz plazme darovalcev krvi.
For the full list of side effects and restrictions with Coagadex, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Coagadex glejte navodilo za uporabo.
Coagadex can only be obtained with a prescription and treatment should be started under the supervision of a doctor experienced in the treatment of rare bleeding disorders. 
Predpisovanje in izdaja zdravila Coagadex je le na recept, zdravljenje z njim pa se sme uvesti in izvajati samo pod nadzorom zdravnika z izkušnjami z zdravljenjem redkih motenj strjevanja krvi.
Further information on the orphan designation can be found here: ema.europa.eu/Find medicine/Human medicines/Rare disease designation Coagadex contains the active substance human coagulation factor X. 
Nadaljnje informacije glede določitve zdravila sirote lahko najdete tukaj: ema.europa.eu/Find medicine/Human medicines/Rare disease designation
By replacing the missing factor X, Coagadex helps the blood to clot and gives temporary control of bleeding. 
Nadomešča manjkajoči faktor X ter tako pripomore k strjevanju krvi in omogoči začasen nadzor nad krvavitvijo.
How does Coagadex work? 
Kako zdravilo Coagadex deluje?
How is Coagadex used? 
Kako se zdravilo Coagadex uporablja?
Coagadex is a medicine used for the treatment and prevention of bleeding (including during and after an operation) in patients with hereditary factor X deficiency. 
Coagadex je zdravilo, ki se uporablja za zdravljenje in preprečevanje krvavitev (tudi med kirurškimi posegi in po njih) pri bolnikih z dednim pomanjkanjem faktorja X. Pomanjkanje faktorja X je motnja strjevanja krvi, ki jo povzroči pomanjkanje faktorja X, beljakovine, ki je potrebna za normalno strjevanje krvi.
This summary was last updated in 06-2008. 
Povzetek je bil nazadnje posodobljen 06-2008.
The study continued for over three years. 
Študija je trajala več kot tri leta.
It is available as light green oval tablets (30, 60 or 90 mg). 
Na voljo je v obliki svetlozelenih ovalnih tablet (30, 60 ali 90 mg).
The studies lasted for six months. 
Študije so trajale šest mesecev.
The European Commission granted a marketing authorisation valid throughout the European Union for Parareg on 22 October 2004. 
Evropska komisija je dovoljenje za promet z zdravilom Parareg, veljavno po vsej Evropski uniji, odobrila dne 22. oktobra 2004.
The marketing authorisation holder is Dompé Biotec S.p.A. 
Imetnik dovoljenja za promet je družba Dompé Biotec S.p.A.
Other information about Parareg: 
Druge informacije o zdravilu Parareg:
It can be used as part of treatment including phosphate binders or vitamin D sterols. 
Uporablja se lahko kot del zdravljenja, ki vključuje vezalce fosfatov ali sterole vitamina D.
Parareg is used in adults and elderly patients: 
Zdravilo Parareg se uporablja pri odraslih in starostnikih:
This means that it mimics the action of calcium in the body. 
To pomeni, da posnema učinkovanje kalcija v telesu.
It can lead to bone and joint pain and deformities of the arms and legs. 
Posledica so lahko bolečine v kosteh in sklepih ter deformacije rok in nog.
This is a condition in which the parathyroid glands in the neck produce too much parathyroid hormone (PTH). 
To je stanje, pri katerem obščitnice v vratu tvorijo preveč paratiroidnega hormona (PTH).
‘Primary' means that the hyperparathyroidism is not caused by any 
„Primarni“ pomeni, da hiperparatiroidizem ni posledica nobenega drugega
The Committee recommended that Parareg be given marketing authorisation. 
Odbor je priporočil, da se za zdravilo Parareg odobri dovoljenje za promet.
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) PARAREG EPAR summary for the public 
EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) PARAREG Povzetek EPAR za javnost
Parareg is taken with food or shortly after a meal. 
Zdravilo Parareg se jemlje s hrano ali takoj po zaužitju obroka.
• to treat secondary hyperparathyroidism. 
• za zdravljenje sekundarnega hiperparatiroidizma.
What benefit has Parareg shown during the studies? 
Kakšne koristi je zdravilo Parareg izkazalo med študijami?
The dose of Parareg should be increased every two to four weeks up to 90 mg three or four times a day as necessary to reduce blood calcium to normal levels. 
Odmerek zdravila Parareg je treba povečevati vsakih dva do štiri tedne do vrednosti 90 mg tri- ali štirikrat dnevno, kolikor je potrebno za znižanje ravni kalcija v krvi na normalno raven.
Of these, 45 went on to a fourth, long-term study looking at the effectiveness of Parareg over a total of almost six years. 
nadaljevalo v četrti, dolgoročni študiji, ki je preučevala učinkovitost zdravila Parareg v trajanju skoraj šest let.
Parareg should not be used in people who may be hypersensitive (allergic) to cinacalcet or any of the other ingredients. 
Zdravila Parareg ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) cinakalcet ali katero koli drugo sestavino zdravila.
What is the risk associated with Parareg? 
Kakšna tveganja so povezana z zdravilom Parareg?